Mobile website
Archive > Volume 24 Issue 11 > 2017,24(11):1315-1319. DOI:10.3872/j.issn.1007-385X.2017.11.013 Prev Next
Clinical Research
Preliminary exploration about efficacy of apatinib plus S-1 to remedy the patients with recurrent and metastatic esophageal cancer as the 2nd line therapy
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To explore efficacy of apatinib plus S-1 to treat the patients with recurrent and metastatic esophageal cancer as 2nd line therapy and its toxic and side effects. Methods: Twenty-four patients with recurrent and metastatic esophageal cancer who diagnosed and remedied in Department of Oncology, the Central Hospital of Kaifeng during June 2015 to December 2016 were collected. Them were divided into Observation and Control groups. Ten patients in the Observation group took orally apatinib plus S-1 as chemotherapy, apatinib was orally taken in 500 mg/d and S-1 taken according to body surface area for 1 to 14 days. Twenty eight days were as one cycle.Fourteen patients in the Control group were treated with routine S-1. Results: After two cycles, efficacy of the chemotherapy was evaluated as CR 0 case; PR 5 cases; SD 3 cases and PD 2 cases. ORR was 50% (5/10) and DCR was 80% (8/10). Before the chemotherapy, baseline diameter sum of 20 target lesions was 71.5 cm, diameter sum of the 20 target lesions became 40.5 cm after 2 cycles of the chemotherapy, and the diameter sum decreased by 43.36%compared with the baseline diameter sum. After six patients completed 4 cycles of the combination chemotherapy,the patients whose efficacy evaluation were effective or stable continued to take orally apatinib alone for maintenance therapy, the longest PFS of the patients was 9 months and their shortest PFS 6 months. Sever drug-related toxic and side effects didn’t be observed. Conclusion: Efficacy of apatinib plus S-1 to treat the patients with recurrent and metastatic esophageal cancer as 2nd line therapy might be better, and its safety and tolerability could be acceptable.
Keywords:
Project Supported:
Clc Number:
